Subtype
Endometrial Carcinoma
CI-CAN-00005159UCECExplore in graph →
109 active trials2 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005159UCECExplore in graph →
Variants & evidence
10 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CCNE1 Amplification2 | ||||||||
| Fadraciclib + TaselisibCombination | Endometrial Serous Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID10181Analysis of 5 uterine serous carcinoma (USC) primary cell lines in vitro indicated enhanced sensitivity to CDK2/9 inhibitor CYC065 in cell lines overexpressing cyclin E1 (CCNE1) in comparison to low C… (full text at CIViC) PMID 27351214 · Cocco et al., 2016 · Open in CIViC | civic |
| Camonsertib + LunresertibCombination | Endometrial Carcinoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID12762In endometrial carcinoma (EMCA) preclinical models, CCNE1 amplification predicted synergistic sensitivity to lunresertib (RP-6306) + camonsertib (RP-3500), with ~80% growth inhibition at low-dose comb… (full text at CIViC) PMID 40169546 · Xu et al., 2025 · Open in CIViC | civic |
| ERBB2 Amplification3 | ||||||||
| (prognostic) | Endometrial Serous Adenocarcinoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID1096In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient… (full text at CIViC) PMID 15746676 · Santin et al., 2005 · Open in CIViC | civic |
| Trastuzumab | Endometrial Serous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID1097HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer. HER2 overexpression in USPC is… (full text at CIViC) PMID 18555254 · Santin et al., 2008 · Open in CIViC | civic |
| Carboplatin/Paclitaxel Regimen + TrastuzumabCombination | Endometrial Serous Adenocarcinoma | Predictive | ||||||
| ERBB2 Overexpression1 | ||||||||
| Carboplatin + Paclitaxel + TrastuzumabCombination | Endometrial Serous Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7386In a randomized phase 2 trial, patients who have uterine serous carcinoma that overexpress erbb2 were allocated carboplatin-paclitaxed with or without trastuzumab. Median progression-free survival was… (full text at CIViC) PMID 29584549 · Fader et al., 2018 · Open in CIViC | civic |
| High1 | ||||||||
| Pembrolizumab | Endometrial Carcinoma | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID12364A phase 3 randomized trial evaluated pembrolizumab (+ adjuvant chemotherapy) vs. placebo (+ adjuvant chemotherapy) in 1,095 newly diagnosed high-risk (non-endometrioid histology with FIGO stage I/II; … (full text at CIViC) PMID 39284383 · Van Gorp et al., 2024 · Open in CIViC | civic |
| POLE R1233*1 | ||||||||
| (oncogenic) | Endometrial AdenocarcinomaCURATED_BROADER | Oncogenic | C | Does Not Support Oncogenicity | 2 | submitted | EID12525Studies submitted to cBioPortal (including 164 TCGA studies) were evaluated for POLE variants co-occurring with features of POLE-mutated tumors and co-occurring B2M variants. A single individual with … (full text at CIViC) PMID 29320758 · Voutsadakis, 2018 · Open in CIViC | civic |
| PTEN Mutation1 | ||||||||
| Everolimus | Endometrial Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID1232Tumors from 35 patients (12 with partial response or stable disease) with advanced endometrial carcinoma were assessed for PTEN mutational status, revealing 12 tumors with non-identical PTEN gene muta… (full text at CIViC) PMID 23238879 · Trédan et al., 2013 · Open in CIViC | civic |
| STMN1 EXPRESSION1 | ||||||||
| Paclitaxel | Endometrial Carcinoma | Predictive | B | Supports Resistance | 3 | accepted | EID85533 patients were retrospectively analyzed for Stathmin expression by IHC. High protein expression was correlated with poor response to paclitaxel but not other chemotherapy. The authors supported this… (full text at CIViC) PMID 24587245 · Werner et al., 2014 · Open in CIViC | civic |
Data updated 2 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| B |
| Supports Sensitivity Response |
| 4 |
| submitted |
EID11322In this randomized, phase II trial, 61 patients with primary stage III or IV or recurrent HER2/neu-positive uterine serous carcinoma. Participants were randomly assigned to receive carboplatin-paclita… (full text at CIViC) PMID 29584549 · Fader et al., 2018 · Open in CIViC |
| civic |